NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $1.30 -0.02 (-1.14%) (As of 10:20 AM ET) Add Compare Share Share Today's Range$1.28▼$1.3350-Day Range$1.08▼$1.3952-Week Range$0.50▼$1.90Volume147,395 shsAverage Volume1.19 million shsMarket Capitalization$83.95 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get SELLAS Life Sciences Group alerts: Email Address SELLAS Life Sciences Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside127.3% Upside$3.00 Price TargetShort InterestHealthy12.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.55) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.85 out of 5 starsMedical Sector742nd out of 911 stocksPharmaceutical Preparations Industry342nd out of 423 stocks 3.5 Analyst's Opinion Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSELLAS Life Sciences Group has only been the subject of 1 research reports in the past 90 days.Read more about SELLAS Life Sciences Group's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.00% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently decreased by 27.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLS. Previous Next 2.7 News and Social Media Coverage News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for SELLAS Life Sciences Group this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for SLS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.55) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about SELLAS Life Sciences Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges as demand ramps up. The market for this type of fuel is projected to grow 1,500% by 2030. Invest before this investment round closes on 9/18.Learn more about how you can become a shareholder before their planned Nasdaq listing About SELLAS Life Sciences Group Stock (NASDAQ:SLS)SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.Read More SLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLS Stock News HeadlinesAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for SELLAS Life Sciences Amid Strong Financial Position and Promising Clinical TrialsAugust 15, 2024 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call TranscriptSeptember 12, 2024 | Deal Maker (Ad)Invest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges as demand ramps up. The market for this type of fuel is projected to grow 1,500% by 2030. Invest before this investment round closes on 9/18.August 14, 2024 | finanznachrichten.deSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | markets.businessinsider.comSLS Stock Earnings: SELLAS Life Sciences Gr Beats EPS for Q2 2024August 13, 2024 | globenewswire.comSELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 6, 2024 | globenewswire.comSELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell LymphomasAugust 5, 2024 | lse.co.ukSellas Life Sciences Group Share ChatSeptember 12, 2024 | Deal Maker (Ad)Invest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges as demand ramps up. The market for this type of fuel is projected to grow 1,500% by 2030. Invest before this investment round closes on 9/18.August 5, 2024 | ca.finance.yahoo.comSLS Aug 2024 0.500 callJuly 31, 2024 | finance.yahoo.comSELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to MarketJuly 31, 2024 | msn.comSELLAS Life Sciences announces $21M registered direct offeringJuly 27, 2024 | finance.yahoo.comCitius Pharmaceuticals Inc (47N.BE)July 25, 2024 | yahoo.comSLS Core Stage ArrivesJuly 22, 2024 | msn.comConnect Life Sciences Strengthens Board with Two New AppointmentsJuly 16, 2024 | globenewswire.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid LeukemiaJuly 8, 2024 | globenewswire.comSELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid LeukemiaJune 24, 2024 | globenewswire.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic LeukemiaSee More Headlines Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/12/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLS CUSIPN/A CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+127.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-17,349.61% Return on Assets-255.78% Debt Debt-to-Equity RatioN/A Current Ratio1.02 Quick Ratio1.02 Sales & Book Value Annual Sales$1 million Price / Sales84.92 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-5.28Miscellaneous Outstanding Shares64,330,000Free Float56,831,000Market Cap$84.92 million OptionableNot Optionable Beta2.38 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Angelos M. Stergiou M.D. (Age 48)ScD h.c., Founder, President, CEO & Director Comp: $921.99kMr. John Thomas Burns CPA (Age 39)Senior VP & CFO Comp: $338.45kMs. Stacy E. YeungVP, Associate General Counsel & Head of ComplianceDr. Dragan Cicic M.D. (Age 61)MBA, Senior Vice President of Clinical Development Comp: $466.43kMr. Andrew ElnatanVP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & QualityKey CompetitorsNeos TherapeuticsNASDAQ:NEOSCorrevio PharmaNASDAQ:CORVMillendo TherapeuticsNASDAQ:MLNDAdaptimmune TherapeuticsNASDAQ:ADAPHeron TherapeuticsNASDAQ:HRTXView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 32,446 shares on 8/9/2024Ownership: 0.056%View All Institutional Transactions SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $1.06 on January 1st, 2024. Since then, SLS stock has increased by 24.5% and is now trading at $1.32. View the best growth stocks for 2024 here. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its earnings results on Tuesday, August, 13th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. When did SELLAS Life Sciences Group's stock split? Shares of SELLAS Life Sciences Group reverse split before market open on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are SELLAS Life Sciences Group's major shareholders? SELLAS Life Sciences Group's top institutional investors include Renaissance Technologies LLC (0.06%). View institutional ownership trends. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLS) was last updated on 9/12/2024 by MarketBeat.com Staff From Our PartnersInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredRecently listed NASDAQ firm is well positioned for growth with game-changing AI platform for e-commerce.With an innovative AI platform, one tiny but growing NASDAQ firm is ushering in a new e-commerce era and is tr...Smallcaps Daily | SponsoredYour Ticket to the Future $75B Air Mobility Market Boom?Looking for the next big investment opportunity? This company could be your chance to catch the electric aviat...Market JAR | SponsoredHow you could collect “AI Royalties” from NVIDIA, META and TSMC...If you've missed out on the first wave of big AI winners... Don't worry. Because there's a much better -...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLS Stock Alerts